Vetting a Myeongdong exosome IV clinic — twelve questions

I want to begin this checklist with a disclaimer the marketing copy never carries. Vetting an exosome IV clinic is not the same exercise as choosing a restaurant in Myeongdong; the stakes are not catastrophic in most scenarios, but the texture of the experience and the substantive quality of the regenerative outcome are materially dependent on questions most prospective patients do not know to ask. The twelve questions below are the questions I would ask if I were arriving in Seoul and choosing a clinic for my own face. They are calibrated to the exosome IV plus microneedling protocol specifically — the protocol the rest of this archive covers — because the vetting axes are protocol-specific. Vetting a clinic for monopolar radiofrequency or MFU runs differently; the exosome IV plus microneedling combination has its own characteristic failure modes the checklist below names. I write in the register of cultural minimalism the archive uses throughout: short answers, named thresholds, the specific phrasing a serious coordinator returns versus the boilerplate a tourist-calibrated clinic returns. The questions are not difficult; the answers are diagnostic.

Question one — Which exosome product does the clinic use, and from which manufacturer?

A serious clinic answers this question on the LINE thread without prompting and without consulting the price list. The answer should specify the manufacturer, the product line, and — crucially — the MFDS regulatory category under which the product is classified. Exosome IV products currently in Korean circulation include offerings from ExoCoBio (ASCE+), Brexogen, and a small handful of others; serious clinics carry one or two consistently rather than rotating across whichever distributor offers the steepest margin in a given quarter. A coordinator who answers 'we use the exosome' without naming the product is signalling either inadequate clinical training or a deliberate refusal to commit on record. Either signal is diagnostic. The tourist-calibrated answer is a vague gesture toward 'premium exosome'; the serious answer names the product and references the MFDS regulatory category.

Question two — What is the MFDS regulatory category of the exosome product?

Exosome products in Korea are regulated under specific MFDS categories — typically as cosmetic raw materials, as medical devices for topical application, or in emerging cases as biopharmaceuticals under the cell and gene therapy framework. The category is consequential because it determines what evidentiary standards the product had to meet for market authorisation, what claims can be made, and what manufacturing and storage requirements apply. A serious coordinator articulates the category in clear terms and is willing to share the MFDS reference number on request. A tourist-calibrated coordinator pivots to the price list when asked, or answers with marketing language that conflates categories. The MFDS reference is on the product packaging; a clinic that hesitates to share it is signalling something.

Question three — Who performs the IV port placement, and what is their licensure?

The IV port placement is the moment of clinical risk in the protocol — not the exosome itself, but the venous access. A senior nursing professional or a licensed physician performs the placement in serious clinics; a tourist-calibrated clinic may delegate to junior staff without the requisite licensure visible. The vetting question is straightforward: who places the port, what is their licensure, and what is their tenure at the clinic. The answer should be returned with specific names available for verification through the Korean Society of Dermatology directory or the MOHW licensure registry. A coordinator who waves the question off as 'a nurse will do it' is not returning enough specificity for an international patient making a clinical decision.

Question four — What is the IV infusion protocol — drip rate, duration, total volume?

A serious clinic answers with specific numbers: drip rate in millilitres per hour, total duration, total volume of the IV bag, carrier solution (typically saline or a buffered isotonic). Exosome IV infusions typically run thirty to forty-five minutes at a controlled drip rate; the carrier choice and exosome concentration are protocol-specific decisions the clinic should articulate. A tourist-calibrated answer is 'about half an hour' without parameters; a serious answer specifies the protocol and is willing to share the written infusion order on request.

Question five — Is the microneedling session conducted before, after, or independent of the IV?

The combination can be sequenced different ways — microneedling before the IV with topical exosome, microneedling after with intradermal injection, or the two modalities across separate visits. Each sequencing has clinical reasoning behind it. A clinic that cannot articulate the rationale is following a vendor-supplied template without the literacy to defend it. The question is not which sequencing is correct; the question is whether the clinic understands their own protocol enough to explain it.

Question six — What is the microneedling depth, and on what zones of the face?

Microneedling depth is calibrated to skin zone — typically 0.5mm on periorbital and forehead, 1.0mm to 1.5mm on cheek and jaw, with the operator adjusting dynamically based on tissue feedback. A serious operator articulates the depth ranges and the zonal map; a tourist-calibrated one runs the device at a single depth across the whole face. Ask what depths on which zones, and how the operator adjusts mid-session. The answer reveals the operator's training depth more than almost any other question.

Question seven — Does the clinic carry biohazard disposal certification for the microneedling cartridges?

Microneedling cartridges are single-use sharps and must be disposed through a certified biohazard waste stream. The certification is not optional in Korea; the MFDS and the municipal authority audit dermatology clinics for compliant sharps disposal. A clinic should be able to share their disposal vendor and most recent audit reference without hesitation. The question is diagnostic of operational rigour: a clinic cutting corners on biohazard is, in my experience, cutting corners on other operational matters the international patient cannot easily verify.

Question eight — What B-complex or vitamin add-ons does the clinic offer, and are they included in the quote?

Many Myeongdong dermatology clinics offer B-complex, vitamin C, or glutathione add-on infusions alongside the exosome IV, and the inclusion or exclusion of these add-ons is a frequent source of pricing confusion. A serious quote specifies whether the IV bag, the IV port placement, and any add-on infusions are included in the headline price, or whether they appear as separate line items. The vetting question is to ask for an itemised quote in writing — line items, prices, currency, and total. The line items the tourist-calibrated clinic adds on at the chair side are the same line items a serious clinic discloses on the pre-trip LINE thread. The pricing transparency is the marker.

Question nine — What is the post-procedure follow-up schedule, and through which channel?

A serious clinic specifies the follow-up cadence on the pre-trip thread: day-one check-in confirming safe travel, day-three on the redness curve, day-seven structured questions on symptoms, day-twenty-one photo prompt for the four-week review. Channel is typically LINE for Japanese, WeChat for Mandarin, KakaoTalk for Korean patients. A clinic that cannot specify the schedule before payment is signalling that the follow-up will be improvised or skipped. The clinic that treats follow-up as a discretionary courtesy is the clinic whose interest ended at the transaction.

Question ten — What is the documented adverse-event reporting workflow?

Serious clinics document adverse events through internal incident reports and, where reportable under MFDS pharmacovigilance requirements, escalate to the regulatory authority. The vetting question is whether the clinic maintains an internal adverse-event log, who reviews it, and what the escalation pathway is for an event that occurs after an international patient has returned home. A clinic that cannot answer this question has not thought about adverse events in advance, which is the worst possible time to encounter that gap. The KHIDI-registered medical-tourism facilitators (the registration the publisher network operates under) maintain parallel logs for international-patient events; the clinic should be willing to align with the facilitator's log on consenting patients.

Question eleven — Is the consultation conducted by the treating physician or by a coordinator?

The consultation should be conducted by the physician who will perform — or supervise — the treatment, not by a coordinator who has been trained on the price list. A serious clinic schedules the consultation at a time the treating physician can be present, with the coordinator providing interpretation rather than acting as the primary consultant. A tourist-calibrated clinic schedules the consultation around the coordinator's availability and produces the physician only briefly for a signature. The vetting question is who will be in the consultation room, and what is their clinical role. The answer determines whether the consent process is substantive or pro forma.

Question twelve — Will the clinic share the written treatment protocol in advance?

The final question is the diagnostic question. A serious clinic shares the written treatment protocol — the IV order, the microneedling depth map, the aftercare instructions, the follow-up schedule — in advance, on the LINE thread, in the language the patient reads. A tourist-calibrated clinic claims this is not their practice or that the protocol is confidential. There is no clinical or regulatory reason to withhold the protocol from a consenting patient asking in advance; the withholding is a marker, not a policy. A clinic that shares the protocol in advance has thought about the patient's clinical literacy as something worth supporting. The twelve questions together produce a clinical profile; the profile is the vetting outcome.

“The questions are not difficult; the answers are diagnostic.”

Saki Watanabe, Seoul notebook

Frequently asked questions

Are these twelve questions specific to exosome IV protocols?

Yes — the checklist is calibrated to the exosome IV plus microneedling combination specifically. Vetting a clinic for MFU, monopolar radiofrequency, or other lifting modalities runs on different axes; the failure modes are different and the documentation thresholds are different. Use the checklist for the protocol it was written for.

Should I ask all twelve questions before booking?

In my reporting experience, the first four or five questions are typically sufficient to sort a serious clinic from a tourist-calibrated one. A coordinator who returns clear, specific answers to the manufacturer, MFDS category, port placement, and infusion protocol questions is signalling clinical literacy; a coordinator who pivots to the price list is signalling something else. The remaining questions refine the picture once the threshold is crossed.

What if the clinic refuses to share the MFDS reference?

The MFDS reference is on the product packaging and is not confidential. A clinic that refuses to share it is signalling either inadequate clinical training or a deliberate refusal to commit on record. Either signal is diagnostic — the prospective patient should weight the refusal accordingly when comparing options across the corridor.

Do all Myeongdong clinics carry biohazard disposal certification?

Compliant clinics do — the MFDS and municipal authorities audit for it. A clinic that hesitates when asked about sharps disposal vendors is signalling a gap in operational rigour. The certification is not difficult to maintain and a clinic that has not maintained it is a clinic that has cut corners that matter.

What about the language of the consultation?

A serious clinic catering to international patients conducts the consultation in the patient's language — through the coordinator's interpretation if necessary, but with the physician's specific clinical reasoning translated rather than flattened into reassurance. The coordinator workflow page in this archive covers the language calibration in more detail.

Should the consultation happen the day before the procedure or the same day?

Same-day consultations are common in Myeongdong's tourist-calibrated workflow; serious clinics typically prefer a separate consultation day, particularly for international patients, to allow the consent process to be substantive rather than rushed. The treatment-day itinerary page covers the scheduling trade-offs.

Does the checklist apply to clinics outside Myeongdong as well?

The clinical questions apply universally to exosome IV plus microneedling protocols anywhere in Korea. The coordinator-workflow and post-trip follow-up questions are particularly relevant for Myeongdong's international-patient context but apply elsewhere too. The MFDS regulatory references are specific to Korea.

Is there a written version of this checklist I can take to the consultation?

The questions above are deliberately written in the order I would ask them. Save the page, print the questions, and bring them to the consultation; a serious clinic welcomes the printed checklist and a tourist-calibrated clinic visibly tenses when it appears. The reaction is itself part of the vetting.